Licensing, Acquisitions, and Other Arrangements - Additional Information (Details) shares in Millions, $ in Millions |
Jun. 01, 2016
USD ($)
compound
shares
|
Apr. 01, 2016
USD ($)
|
---|---|---|
Stemcentrx | ||
Business Acquisition [Line Items] | ||
Number of early-stage clinical compounds in solid tumor indications acquired | compound | 4 | |
Shares issued as consideration (in shares) | shares | 62.4 | |
Additional payment | $ 4,000 | |
Milestone payments | $ 620 | |
Stemcentrx | IPR&D | ||
Business Acquisition [Line Items] | ||
Number of early-stage clinical compounds in solid tumor indications acquired | compound | 4 | |
BI | ||
Business Acquisition [Line Items] | ||
Initial upfront payment | $ 595 | |
Additional payment | 18 | |
Milestone payments | 606 | |
Royalty payments | 2,800 | |
BI | Maximum | ||
Business Acquisition [Line Items] | ||
Additional payment | $ 1,600 |